Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia

Ronald B Goldberg, John R. Guyton, Theodore Mazzone, Ruth S. Weinstock, Adam B. Polis, Diane Tipping, Joanne E. Tomassini, Andrew M. Tershakovec

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

OBJECTIVE - To investigate relationships between baseline factors and treatment-associated efficacy changes in type 2 diabetes. RESEARCH DESIGN AND METHODS - Multivariable analyses of treatment response in 1,229 type 2 diabetic patients with hypercholesterolemia who received ezetimibe/simvastatin or atorvastatin in a randomized double-blind 6-week study. RESULTS - Increasing age was related to improvements in all lipid assessments. Men had greater triglyceride and non-HDL cholesterol reductions than women, and black/Hispanic patients had less favorable lipid effects than other races/ethnicities. Increasing baseline LDL cholesterol was associated with improvements in most lipids; higher baseline non-HDL cholesterol with improved HDL cholesterol and triglycerides; higher baseline HDL cholesterol with greater non-HDL cholesterol and high-sensitivity C-reactive protein (hs-CRP) reductions; and higher baseline hs-CRP with smaller LDL cholesterol, non-HDL cholesterol, and apolipoprotein B reductions. Patients with high baseline non-HDL cholesterol or triglycerides less frequently attained LDL cholesterol targets. Obesity was inversely related to HDL cholesterol and hs-CRP changes, and higher baseline A1C to smaller apolipoprotein B reductions. Metabolic syndrome was not a significant predictor. CONCLUSIONS - Treatment responses in type 2 diabetic patients were related to baseline factors, although treatment effects (ezetimibe/simvastatin being more effective than atorvastatin) remained consistent. The presence of predictive factors should be considered in planning lipid-altering therapy.

Original languageEnglish
Pages (from-to)1021-1024
Number of pages4
JournalDiabetes Care
Volume33
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Simvastatin
Hypercholesterolemia
Type 2 Diabetes Mellitus
Cholesterol
C-Reactive Protein
LDL Cholesterol
HDL Cholesterol
Lipids
Triglycerides
Apolipoproteins B
Therapeutics
Hispanic Americans
Research Design
Obesity
Ezetimibe
Atorvastatin Calcium

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. / Goldberg, Ronald B; Guyton, John R.; Mazzone, Theodore; Weinstock, Ruth S.; Polis, Adam B.; Tipping, Diane; Tomassini, Joanne E.; Tershakovec, Andrew M.

In: Diabetes Care, Vol. 33, No. 5, 01.05.2010, p. 1021-1024.

Research output: Contribution to journalArticle

Goldberg, Ronald B ; Guyton, John R. ; Mazzone, Theodore ; Weinstock, Ruth S. ; Polis, Adam B. ; Tipping, Diane ; Tomassini, Joanne E. ; Tershakovec, Andrew M. / Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. In: Diabetes Care. 2010 ; Vol. 33, No. 5. pp. 1021-1024.
@article{3087e3c48d6941e1b450027d0896a31e,
title = "Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia",
abstract = "OBJECTIVE - To investigate relationships between baseline factors and treatment-associated efficacy changes in type 2 diabetes. RESEARCH DESIGN AND METHODS - Multivariable analyses of treatment response in 1,229 type 2 diabetic patients with hypercholesterolemia who received ezetimibe/simvastatin or atorvastatin in a randomized double-blind 6-week study. RESULTS - Increasing age was related to improvements in all lipid assessments. Men had greater triglyceride and non-HDL cholesterol reductions than women, and black/Hispanic patients had less favorable lipid effects than other races/ethnicities. Increasing baseline LDL cholesterol was associated with improvements in most lipids; higher baseline non-HDL cholesterol with improved HDL cholesterol and triglycerides; higher baseline HDL cholesterol with greater non-HDL cholesterol and high-sensitivity C-reactive protein (hs-CRP) reductions; and higher baseline hs-CRP with smaller LDL cholesterol, non-HDL cholesterol, and apolipoprotein B reductions. Patients with high baseline non-HDL cholesterol or triglycerides less frequently attained LDL cholesterol targets. Obesity was inversely related to HDL cholesterol and hs-CRP changes, and higher baseline A1C to smaller apolipoprotein B reductions. Metabolic syndrome was not a significant predictor. CONCLUSIONS - Treatment responses in type 2 diabetic patients were related to baseline factors, although treatment effects (ezetimibe/simvastatin being more effective than atorvastatin) remained consistent. The presence of predictive factors should be considered in planning lipid-altering therapy.",
author = "Goldberg, {Ronald B} and Guyton, {John R.} and Theodore Mazzone and Weinstock, {Ruth S.} and Polis, {Adam B.} and Diane Tipping and Tomassini, {Joanne E.} and Tershakovec, {Andrew M.}",
year = "2010",
month = "5",
day = "1",
doi = "10.2337/dc09-1762",
language = "English",
volume = "33",
pages = "1021--1024",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia

AU - Goldberg, Ronald B

AU - Guyton, John R.

AU - Mazzone, Theodore

AU - Weinstock, Ruth S.

AU - Polis, Adam B.

AU - Tipping, Diane

AU - Tomassini, Joanne E.

AU - Tershakovec, Andrew M.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - OBJECTIVE - To investigate relationships between baseline factors and treatment-associated efficacy changes in type 2 diabetes. RESEARCH DESIGN AND METHODS - Multivariable analyses of treatment response in 1,229 type 2 diabetic patients with hypercholesterolemia who received ezetimibe/simvastatin or atorvastatin in a randomized double-blind 6-week study. RESULTS - Increasing age was related to improvements in all lipid assessments. Men had greater triglyceride and non-HDL cholesterol reductions than women, and black/Hispanic patients had less favorable lipid effects than other races/ethnicities. Increasing baseline LDL cholesterol was associated with improvements in most lipids; higher baseline non-HDL cholesterol with improved HDL cholesterol and triglycerides; higher baseline HDL cholesterol with greater non-HDL cholesterol and high-sensitivity C-reactive protein (hs-CRP) reductions; and higher baseline hs-CRP with smaller LDL cholesterol, non-HDL cholesterol, and apolipoprotein B reductions. Patients with high baseline non-HDL cholesterol or triglycerides less frequently attained LDL cholesterol targets. Obesity was inversely related to HDL cholesterol and hs-CRP changes, and higher baseline A1C to smaller apolipoprotein B reductions. Metabolic syndrome was not a significant predictor. CONCLUSIONS - Treatment responses in type 2 diabetic patients were related to baseline factors, although treatment effects (ezetimibe/simvastatin being more effective than atorvastatin) remained consistent. The presence of predictive factors should be considered in planning lipid-altering therapy.

AB - OBJECTIVE - To investigate relationships between baseline factors and treatment-associated efficacy changes in type 2 diabetes. RESEARCH DESIGN AND METHODS - Multivariable analyses of treatment response in 1,229 type 2 diabetic patients with hypercholesterolemia who received ezetimibe/simvastatin or atorvastatin in a randomized double-blind 6-week study. RESULTS - Increasing age was related to improvements in all lipid assessments. Men had greater triglyceride and non-HDL cholesterol reductions than women, and black/Hispanic patients had less favorable lipid effects than other races/ethnicities. Increasing baseline LDL cholesterol was associated with improvements in most lipids; higher baseline non-HDL cholesterol with improved HDL cholesterol and triglycerides; higher baseline HDL cholesterol with greater non-HDL cholesterol and high-sensitivity C-reactive protein (hs-CRP) reductions; and higher baseline hs-CRP with smaller LDL cholesterol, non-HDL cholesterol, and apolipoprotein B reductions. Patients with high baseline non-HDL cholesterol or triglycerides less frequently attained LDL cholesterol targets. Obesity was inversely related to HDL cholesterol and hs-CRP changes, and higher baseline A1C to smaller apolipoprotein B reductions. Metabolic syndrome was not a significant predictor. CONCLUSIONS - Treatment responses in type 2 diabetic patients were related to baseline factors, although treatment effects (ezetimibe/simvastatin being more effective than atorvastatin) remained consistent. The presence of predictive factors should be considered in planning lipid-altering therapy.

UR - http://www.scopus.com/inward/record.url?scp=77954915745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954915745&partnerID=8YFLogxK

U2 - 10.2337/dc09-1762

DO - 10.2337/dc09-1762

M3 - Article

C2 - 20150290

AN - SCOPUS:77954915745

VL - 33

SP - 1021

EP - 1024

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 5

ER -